APR Applied Pharma Research s.a. , the Swiss, independent developer of science driven, patent protected healthcare products, is today proud to announce the business partnership with DKSH, the leading Market Expansion Services provider with a focus on Asia. The partnership involves marketing, sales, distribution and logistics for APR’s patented Diclofenac 50 mg powder oral solution for acute migraine treatment and other pain areas, in Malaysia, the Philippines, Myanmar and Vietnam under the DKSH subsidiary Favorex.